urveillance of the Eye and Viion in Clinical Trial of CP-675,206 for Metatatic Melanoma Original Reearch Article

Purpoe To determine the ocular afety of CP-675,206 (Pfizer, New York, New York, UA), a fully human anti–cytotoxic T lymphocyte-aociated antigen 4 monoclonal antibody in clinical trial of immunotherapy of metatatic melanoma. Deign Propective, nonrandomized tudy of the eye and viion in phae I/II clinical trial of CP-675,206 in metatatic melanoma conducted at the Univerity of California, Lo Angele. Method Patient with regional or ditant metatatic melanoma were enrolled in phae I/II clinical trial evaluating the afety and antitumor efficacy of CP-675,206 alone or in combination with melanoma antigen peptide-puled dendritic cell vaccine. Ophthalmic evaluation wa performed at the onet of CP-675,206 immunotherapy (baeline evaluation), two month or more after the onet of CP-675,206 immunotherapy (end-tudy evaluation), and at two- to three-month interval thereafter in patient who continued to receive CP-675,206 immunotherapy (pottudy evaluation). Baeline and end-tudy evaluation included comprehenive ophthalmic examination, pychophyical and electrophyiologic viual function aement, fundu photography, fluorecein angiography, and viual function aement. Reult Twenty patient with metatatic melanoma ariing from the kin, mucoa, eye, or unknown ite were evaluated. ytemic toxicity attributed to CP-675,206 included dermatologic manifetation, diarrhea, and autoimmune hepatiti with panhypopituitarim. A ubet of patient receiving CP-675,206 demontrated antitumor efficacy with partial repone or complete repone of metatatic melanoma. Comparion of ophthalmic baeline with end-tudy evaluation in all 20 patient and limited-term pottudy evaluation howed no advere effect of CP-675,206 immunotherapy on the eye or viion. Concluion In thi tudy, CP-675,206 immunotherapy for metatatic melanoma did not adverely affect the eye or viion.